Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-04-24 19:40 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

ANABAnaptysBio, Inc.2026-04-20 13:15 EST

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Stock data

Close: 57.74 USD
Market cap: 1.49B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Related news

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

AnaptysBio, Inc.